Sign in
BCDAW Stock Price, Chart, Stats & News
BioCardia, Inc.
Save
BioCardia, Inc. (BCDAW) does not currently pay a dividend.
10,116
Market cap
–
Current P/E
–
Forward P/E
BCDAW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -241.08% |
ROE | -28372.41% |
D/E | 0.59x |
Interest coverage ratio | – |
BCDAW valuation
P/E | – |
P/S | – |
P/B | 13.94x |
P/CF | -1.68x |
P/FCF | -0.90x |
P/OCF | -1.68x |
PEG | -0.06x |
EV multiple | -1.09x |
About
BioCardia, Inc. is a regenerative medicine enterprise, currently in the clinical development phase, dedicated to devising cell-based and cell-derived treatments for cardiac and pulmonary ailments. Its primary therapeutic offering is CardiAMP, an autologous mononuclear cell therapy system designed to address heart failure and persistent myocardial ischemia. In parallel, the company is advancing allogeneic cell therapies for various heart and lung diseases, including an investigational platform utilizing culture-expanded bone marrow-derived mesenchymal cells, which is presently in Phase I/II trials for ischemic heart failure.
Similar securities
Based on sector and market capitalization
Report issue